This study redefines the immunomodulatory repertoire of PAC by uncovering a microbiota-dependent, gut-liver axis that licenses B-cell-driven CD8+T-cell immunity against hepatocellular carcinoma. Here, CD8A is linked to hepatocellular carcinoma.